Achilles Therapeutics plc

NasdaqGS:ACHL Stock Report

Market Cap: US$32.1m

Achilles Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Achilles Therapeutics has a total shareholder equity of $142.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $161.5M and $19.1M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$131.54m
EquityUS$142.37m
Total liabilitiesUS$19.09m
Total assetsUS$161.46m

Recent financial health updates

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Financial Position Analysis

Short Term Liabilities: ACHL's short term assets ($145.6M) exceed its short term liabilities ($17.0M).

Long Term Liabilities: ACHL's short term assets ($145.6M) exceed its long term liabilities ($2.1M).


Debt to Equity History and Analysis

Debt Level: ACHL is debt free.

Reducing Debt: ACHL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACHL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ACHL has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 24.3% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.